Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
- Author:
Jun Sung MOON
1
;
Sunghwan SUH
;
Sang Soo KIM
;
Heung Yong JIN
;
Jeong Mi KIM
;
Min Hee JANG
;
Kyung Ae LEE
;
Ju Hyung LEE
;
Seung Min CHUNG
;
Young Sang LYU
;
Jin Hwa KIM
;
Sang Yong KIM
;
Jung Eun JANG
;
Tae Nyun KIM
;
Sung Woo KIM
;
Eonju JEON
;
Nan Hee CHO
;
Mi-Kyung KIM
;
Hye Soon KIM
;
Il Seong NAM-GOONG
;
Eun Sook KIM
;
Jin Ook CHUNG
;
Dong-Hyeok CHO
;
Chang Won LEE
;
Young Il KIM
;
Dong Jin CHUNG
;
Kyu Chang WON
;
In Joo KIM
;
Tae Sun PARK
;
Duk Kyu KIM
;
Hosang SHON
Author Information
- Publication Type:Original Article
- From:Diabetes & Metabolism Journal 2020;44(S1):e46-
- CountryRepublic of Korea
-
Abstract:
Background:Only few studies have shown the efficacy and safety of glucose-control strategies using the quadruple drug combination. Therefore, the aim of the present study was to investigate the usefulness of the quadruple combination therapy with oral hypoglycemic agents (OHAs) in patients with uncontrolled type 2 diabetes mellitus (T2DM).
Methods:From March 2014 to December 2018, data of patients with T2DM, who were treated with quadruple hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels before and 12 months after quadruple treatment with OHAs. The safety, maintenance rate, and therapeutic patterns after failure of the quadruple therapy were also evaluated.
Results:In total, 357 patients were enrolled for quadruple OHA therapy, and the baseline HbA1c level was 9.0%±1.3% (74.9± 14.1 mmol/mol). After 12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was significantly reduced from 8.9%±1.2% to 7.8%±1.3% (mean change, –1.1%±1.2%; P<0.001). The number of patients with HbA1c <7% increased significantly from 5 to 68 (P<0.005). In addition, lipid profiles and liver enzyme levels were also improved whereas no changes in body weight. There was no significant safety issue in patients treated with quadruple OHA therapy.
Conclusion:This study shows the therapeutic efficacy of the quadruple OHA regimen T2DM and demonstrates that it can be an option for the management of T2DM patients who cannot use insulin or reject injectable therapy.
